128 related articles for article (PubMed ID: 25612832)
1. NOXIN as a cofactor of DNA polymerase-primase complex could promote hepatocellular carcinoma.
Zhang ZZ; Huang J; Wang YP; Cai B; Han ZG
Int J Cancer; 2015 Aug; 137(4):765-75. PubMed ID: 25612832
[TBL] [Abstract][Full Text] [Related]
2. Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.
Wang K; Lim HY; Shi S; Lee J; Deng S; Xie T; Zhu Z; Wang Y; Pocalyko D; Yang WJ; Rejto PA; Mao M; Park CK; Xu J
Hepatology; 2013 Aug; 58(2):706-17. PubMed ID: 23505090
[TBL] [Abstract][Full Text] [Related]
3. PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK.
Zhou Q; Zhou Q; Liu Q; He Z; Yan Y; Lin J; Chen Z; He C; Mao K; Wang J; Zhou Z; Xiao Z; Zhang J
Theranostics; 2020; 10(22):10345-10359. PubMed ID: 32929353
[No Abstract] [Full Text] [Related]
4. [Identification of the regions of copy number amplification associated with hepatocellular carcinoma].
Zhang SG; Gao YT; Song WQ; Du Z; Yang B; Wang YJ; Zhu ZY
Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):566-70. PubMed ID: 20021941
[TBL] [Abstract][Full Text] [Related]
5. Mediator subunit 23 overexpression as a novel target for suppressing proliferation and tumorigenesis in hepatocellular carcinoma.
Guo Y; Wang J; Li H; Liu W; Chen D; Zhao K; Liang X; Zhang Q; Yang Y; Chen G
J Gastroenterol Hepatol; 2015 Jun; 30(6):1094-103. PubMed ID: 25684393
[TBL] [Abstract][Full Text] [Related]
6. EVI1, a target gene for amplification at 3q26, antagonizes transforming growth factor-β-mediated growth inhibition in hepatocellular carcinoma.
Yasui K; Konishi C; Gen Y; Endo M; Dohi O; Tomie A; Kitaichi T; Yamada N; Iwai N; Nishikawa T; Yamaguchi K; Moriguchi M; Sumida Y; Mitsuyoshi H; Tanaka S; Arii S; Itoh Y
Cancer Sci; 2015 Jul; 106(7):929-37. PubMed ID: 25959919
[TBL] [Abstract][Full Text] [Related]
7. CSIG promotes hepatocellular carcinoma proliferation by activating c-MYC expression.
Cheng Q; Yuan F; Lu F; Zhang B; Chen T; Chen X; Cheng Y; Li N; Ma L; Tong T
Oncotarget; 2015 Mar; 6(7):4733-44. PubMed ID: 25749381
[TBL] [Abstract][Full Text] [Related]
8. Overlapping high-resolution copy number alterations in cancer genomes identified putative cancer genes in hepatocellular carcinoma.
Chen CF; Hsu EC; Lin KT; Tu PH; Chang HW; Lin CH; Chen YJ; Gu DL; Lin CH; Wu JY; Chen YT; Hsu MT; Jou YS
Hepatology; 2010 Nov; 52(5):1690-701. PubMed ID: 20799341
[TBL] [Abstract][Full Text] [Related]
9. Gain of UBE2D1 facilitates hepatocellular carcinoma progression and is associated with DNA damage caused by continuous IL-6.
Zhou C; Bi F; Yuan J; Yang F; Sun S
J Exp Clin Cancer Res; 2018 Nov; 37(1):290. PubMed ID: 30482241
[TBL] [Abstract][Full Text] [Related]
10. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.
Liu WR; Tian MX; Yang LX; Lin YL; Jin L; Ding ZB; Shen YH; Peng YF; Gao DM; Zhou J; Qiu SJ; Dai Z; He R; Fan J; Shi YH
Oncotarget; 2015 Jan; 6(2):846-61. PubMed ID: 25514599
[TBL] [Abstract][Full Text] [Related]
11. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
12. Infrequent amplification of JUN in hepatocellular carcinoma.
Endo M; Yasui K; Nakajima T; Gen Y; Tsuji K; Dohi O; Zen K; Mitsuyoshi H; Minami M; Itoh Y; Taniwaki M; Tanaka S; Arii S; Okanoue T; Yoshikawa T
Anticancer Res; 2009 Dec; 29(12):4989-94. PubMed ID: 20044606
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of the putative oncogene COTE1 contributes to human hepatocarcinogenesis through modulation of WWOX signaling.
Zhang H; Tian Y; Shen J; Wang Y; Xu Y; Wang Y; Han Z; Li X
Int J Oncol; 2014 Aug; 45(2):719-31. PubMed ID: 24899407
[TBL] [Abstract][Full Text] [Related]
14. Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma.
Ma NF; Hu L; Fung JM; Xie D; Zheng BJ; Chen L; Tang DJ; Fu L; Wu Z; Chen M; Fang Y; Guan XY
Hepatology; 2008 Feb; 47(2):503-10. PubMed ID: 18023026
[TBL] [Abstract][Full Text] [Related]
15. Homeobox B9 is overexpressed in hepatocellular carcinomas and promotes tumor cell proliferation both in vitro and in vivo.
Li F; Dong L; Xing R; Wang L; Luan F; Yao C; Ji X; Bai L
Biochem Biophys Res Commun; 2014 Feb; 444(2):241-7. PubMed ID: 24462859
[TBL] [Abstract][Full Text] [Related]
16. SMAD5 gene expression, rearrangements, copy number, and amplification at fragile site FRA5C in human hepatocellular carcinoma.
Zimonjic DB; Durkin ME; Keck-Waggoner CL; Park SW; Thorgeirsson SS; Popescu NC
Neoplasia; 2003; 5(5):390-6. PubMed ID: 14670176
[TBL] [Abstract][Full Text] [Related]
17. Argonaute2 promotes tumor metastasis by way of up-regulating focal adhesion kinase expression in hepatocellular carcinoma.
Cheng N; Li Y; Han ZG
Hepatology; 2013 May; 57(5):1906-18. PubMed ID: 23258480
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of ARNT2 promotes tumor growth and predicts poor prognosis in human hepatocellular carcinoma.
Li W; Liang Y; Yang B; Sun H; Wu W
J Gastroenterol Hepatol; 2015 Jun; 30(6):1085-93. PubMed ID: 25611915
[TBL] [Abstract][Full Text] [Related]
19. Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review).
Zimonjic DB; Popescu NC
Int J Oncol; 2012 Aug; 41(2):393-406. PubMed ID: 22580498
[TBL] [Abstract][Full Text] [Related]
20. RASSF1A expression inhibits the growth of hepatocellular carcinoma from Qidong County.
Xue WJ; Li C; Zhou XJ; Guan HG; Qin L; Li P; Wang ZW; Qian HX
J Gastroenterol Hepatol; 2008 Sep; 23(9):1448-58. PubMed ID: 17683489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
